PriceTargets.com logo

NYSE:MYOV - Myovant Sciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $25.60
  • Forecasted Upside: 17.70 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$21.75 As of 09/16/2021 03:03 PM ET
▼ -0.08 (-0.37%)

This chart shows the closing price for MYOV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Myovant Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MYOV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MYOV

Analyst Price Target is $25.60
▲ +17.70% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Myovant Sciences in the last 3 months. The average price target is $25.60, with a high forecast of $32.00 and a low forecast of $18.00. The average price target represents a 17.70% upside from the last price of $21.75.

This chart shows the closing price for MYOV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 polled investment analysts is to buy stock in Myovant Sciences. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/18/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
8/17/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/9/2021SVB LeerinkInitiated CoverageMarket Perform$24.00High
8/25/2021JMP SecuritiesReiterated RatingBuyLow
8/20/2021The Goldman Sachs GroupInitiated CoverageNeutral$18.00Low
5/13/2021CitigroupLower Price TargetNeutral ➝ Neutral$30.00 ➝ $24.00Low
5/3/2021JPMorgan Chase & Co.Lower Price TargetOverweight$38.00 ➝ $32.00Low
2/12/2021SVB LeerinkLower Price TargetMarket Perform$28.00 ➝ $26.00Low
1/8/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$30.00 ➝ $28.00High
1/6/2021The Goldman Sachs GroupDowngradeBuy ➝ Neutral$30.00N/A
12/21/2020Robert W. BairdBoost Price TargetOutperform$24.00 ➝ $30.00Medium
8/12/2020SVB LeerinkLower Price TargetOutperform$29.00 ➝ $28.00Low
7/7/2020SVB LeerinkBoost Price TargetOutperform$27.00 ➝ $29.00High
6/23/2020Evercore ISIBoost Price TargetOutperform ➝ Positive$45.00 ➝ $55.00High
6/2/2020CitigroupBoost Price TargetNeutral$9.00 ➝ $20.00High
6/1/2020Evercore ISIBoost Price Target$30.00 ➝ $35.00Medium
6/1/2020JPMorgan Chase & Co.Boost Price TargetOverweight$19.00 ➝ $26.00High
5/19/2020SVB LeerinkLower Price TargetOutperform$28.00 ➝ $27.00High
2/10/2020CowenReiterated RatingBuyHigh
2/2/2020CitigroupInitiated CoverageBuy ➝ Neutral$15.00Medium
11/19/2019JMP SecuritiesReiterated RatingBuy$34.00Low
11/19/2019The Goldman Sachs GroupReiterated RatingPositive ➝ Buy$18.00 ➝ $20.00Medium
11/12/2019CowenReiterated RatingBuyHigh
10/25/2019The Goldman Sachs GroupSet Price TargetBuy$18.00N/A
9/6/2019CowenReiterated RatingBuyHigh
8/28/2019The Goldman Sachs GroupInitiated CoverageBuy$20.00High
8/19/2019SVB LeerinkInitiated CoverageOutperform$26.00High
5/30/2019CitigroupInitiated CoverageBuy$25.00High
4/11/2019Evercore ISIInitiated CoverageOutperformHigh
2/13/2019BarclaysUpgradeEqual Weight ➝ Overweight$22.00 ➝ $25.00High
2/11/2019JMP SecuritiesReiterated RatingBuy$25.00Low
11/19/2018CitigroupLower Price TargetBuy ➝ Buy$44.00 ➝ $42.00Medium
11/9/2018CowenReiterated RatingBuyHigh
10/26/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$25.00Medium
9/13/2018JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$39.00High
4/25/2018CitigroupBoost Price TargetBuy ➝ Buy$17.00 ➝ $44.00Low
4/5/2018BarclaysDowngradeOverweight ➝ Equal Weight$18.00High
11/14/2017CowenReiterated RatingBuyN/A
11/10/2017Robert W. BairdReiterated RatingBuy$20.00N/A
10/4/2017JMP SecuritiesReiterated RatingOutperform$23.00 ➝ $25.00Low
10/4/2017Robert W. BairdReiterated RatingBuy$20.00Low
10/3/2017CowenReiterated RatingBuyLow
8/16/2017Evercore ISIInitiated CoverageOutperform ➝ OutperformHigh
11/21/2016CowenInitiated CoverageOutperformN/A
11/21/2016CitigroupInitiated CoverageBuy$17.00N/A
11/21/2016JMP SecuritiesInitiated CoverageOutperform$23.00N/A
11/21/2016BarclaysInitiated CoverageOverweight$18.00N/A
11/21/2016Robert W. BairdInitiated CoverageOutperform$20.00N/A
(Data available from 9/16/2016 forward)

News Sentiment Rating

0.64 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/19/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/18/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/18/2021
  • 4 very positive mentions
  • 8 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
8/17/2021
  • 10 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
9/16/2021

Current Sentiment

  • 10 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Myovant Sciences logo
Myovant Sciences, Inc. is a clinical-stage biopharmaceutical company. The firm focuses on the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM (relugolix), a oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $21.75
Low: $21.25
High: $21.90

50 Day Range

MA: $21.86
Low: $18.94
High: $26.99

52 Week Range

Now: $21.75
Low: $13.42
High: $30.90

Volume

10,404 shs

Average Volume

819,740 shs

Market Capitalization

$2.00 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.87

Frequently Asked Questions

What sell-side analysts currently cover shares of Myovant Sciences?

The following Wall Street research analysts have issued stock ratings on Myovant Sciences in the last twelve months: Citigroup Inc., JMP Securities, JPMorgan Chase & Co., Robert W. Baird, SVB Leerink LLC, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for MYOV.

What is the current price target for Myovant Sciences?

5 Wall Street analysts have set twelve-month price targets for Myovant Sciences in the last year. Their average twelve-month price target is $25.60, suggesting a possible upside of 17.7%. JPMorgan Chase & Co. has the highest price target set, predicting MYOV will reach $32.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $18.00 for Myovant Sciences in the next year.
View the latest price targets for MYOV.

What is the current consensus analyst rating for Myovant Sciences?

Myovant Sciences currently has 3 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MYOV will outperform the market and that investors should add to their positions of Myovant Sciences.
View the latest ratings for MYOV.

What other companies compete with Myovant Sciences?

Other companies that are similar to Myovant Sciences include Jazz Pharmaceuticals, BridgeBio Pharma, Mawson Infrastructure Group, Sarepta Therapeutics, Arrowhead Pharmaceuticals, HUTCHMED, Ultragenyx Pharmaceutical, Blueprint Medicines, Perrigo, Legend Biotech, Allakos, I-Mab, Cerevel Therapeutics, Ionis Pharmaceuticals and Alkermes.

How do I contact Myovant Sciences' investor relations team?

Myovant Sciences' physical mailing address is 11-12 ST. JAMES SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The company's listed phone number is 442074003351 and its investor relations email address is [email protected] The official website for Myovant Sciences is www.myovant.com.